FDA Grants Compassionate Use for Retatrutide in 79-Year-Old Patient
LLY•The FDA approved compassionate use of Eli Lilly’s experimental triple-agonist obesity drug retatrutide for a 79-year-old patient under its compassionate use program. Late-stage data showed once-weekly retatrutide injections delivered up to 28% weight loss over 80 weeks, underscoring the drug’s potential in obesity treatment.
1. Compassionate Use Approval
The FDA invoked its compassionate use program to grant a 79-year-old patient access to retatrutide, allowing treatment prior to full market authorization. This decision highlights severe obesity cases with limited options and underscores regulatory flexibility for breakthrough therapies.
2. Mechanism and Clinical Results
Retatrutide is a once-weekly injectable targeting three hormone pathways—GIP, GLP-1 and glucagon—to enhance weight loss. Late-stage trial results demonstrated up to 28% average body weight reduction over 80 weeks, a significant advance over existing treatments.
3. Commercial and Regulatory Outlook
While compassionate use does not alter retatrutide’s formal development timeline, it raises the therapy’s profile among clinicians and patients. Eli Lilly continues pivotal trials and expects regulatory submissions based on full data later this year, with potential market launch in 2027.
Related News
Sources
